OncoMatch/Clinical Trials/NCT06509009
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Is NCT06509009 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Nimotuzumab for nasopharyngeal carcinoma by ajcc v8 stage.
Treatment: Nimotuzumab — The goal of this study is to learn the efficacy and safety of nimotuzumab combined with toripalimab and gemcitabine/cisplatin regimen treatment recurrent/distant-metastasis nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: EGFR expression positive
EGFR expression positive
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: radiotherapy
Subjects who have received radiotherapy ... within the past six months
Cannot have received: chemotherapy
Subjects who have received ... chemotherapy ... within the past six months
Cannot have received: immunosuppressive agents
Subjects who have received ... immunosuppressive agents ... within the past six months
Cannot have received: monoclonal antibodies
Subjects who have received ... monoclonal antibodies ... within the past six months
Cannot have received: EGFR tyrosine kinase inhibitor
Subjects who have received ... oral epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) ... within the past six months
Cannot have received: anti-angiogenic drugs
Subjects who have received ... anti-angiogenic drugs within the past six months
Lab requirements
Blood counts
white blood cell count ≥ 3 × 10^9/l; absolute neutrophil count ≥ 1.5 × 10^9/l; platelet count ≥ 100 × 10^9/l; hemoglobin level ≥ 90 g/l
Kidney function
serum creatinine level ≤ 1.2 mmol/l or creatinine clearance ≥ 60 ml/min
Liver function
serum total bilirubin ≤ 1.5 × uln (in case of liver metastasis, ≤ 3.0 × uln); ast and alt ≤ 2.5 × uln (in case of liver metastasis, ≤ 5.0 × uln)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06509009 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR expression positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify